Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer
Shots:
- Novartis reported updated P-III (NATALEE) study data showing extended efficacy of Kisqali (ribociclib) with ET vs ET alone to treat patients (n=5,101) with stage II and III HR+/HER2- early breast cancer (EBC)
- Study depicted reduced distant recurrence by 28.5% in EBC patients, with consistent benefits across subgroups; safety aligned with prior data, with AEs incl. neutropenia (44.4%), liver-related issues (8.6%) & QT interval prolongation (1.0%). These findings were presented at SABCS 2024
- Kisqali (ribociclib) is a selective CDK4/6 inhibitor that slows cancer progression by blocking proteins that drive uncontrolled cell growth and division
Ref: Novartis | Image: Novartis
Related News:- PTC Therapeutics Join Forces with Novartis to Develop PTC518 for Treating Huntington's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
